Analysts’ Viewpoint on Europe and Middle East & Africa Meningitis Diagnostic Testing Market
Companies in the EMEA meningitis diagnostic testing market are taking advantage of governments’ stimulus packages to stay financially afloat during the ongoing COVID-19 pandemic. Currently available rapid diagnostics tests (RDTs) to detect meningococcal meningitis are found to have a short shelf life. Hence, companies in the EMEA meningitis diagnostic testing market are increasing research to develop RDTs with good sensitivities and specificities. Rapid, accurate, and specific identification of the causative organism are necessary to ensure an effective public health response. Apart from diagnostic tests, healthcare companies are diversifying in the implementation of conjugate polysaccharide vaccines to revolutionize public health management.
The technology of diagnostic kit for bacterial meningitis using real-time HRM PCR holds potential to improve clinical numbers. Companies in the EMEA meningitis diagnostic testing market should collaborate with researchers to develop new kits that help to cut down costs of molecular diagnosis of bacterial meningitis. Stakeholders are taking efforts to increase the availability of these kits amongst the common public and mainly at private laboratories.
Companies in the EMEA meningitis diagnostic testing market are increasing R&D in developing kits that make use of a single fluorophore to detect the target genes through melting temperature analysis of the bacterial target gene. It has been found that each gene detected has a different melting temperature, easily visualized in a graph at the end of the amplification.
Common symptoms of COVID-19 and meningitis are creating concerns for both healthcare providers and the general public. Thus, robust diagnostic testing has become the need of the hour during the ongoing pandemic. Stakeholders in the EMEA meningitis diagnostic testing market are increasing the availability of products to meet healthcare needs of individuals.
In order to reduce stress on healthcare facilities, stakeholders in the EMEA meningitis diagnostic testing market are increasing awareness and facilitating early diagnosis to prevent the spread of diseases. They are maintaining optimum inventory levels to ensure continuity in supply chains. Companies are rethinking their manufacturing activities since financial situations have been squeezed for many. They are taking data-driven decisions to sustain volatile market sentiments.
Transporting samples to laboratories have many logistical challenges in countries falling under the meningitis belt in Africa, as latex agglutination requires refrigeration and lab equipment. Moreover, this technique is dependent on a sample of spinal fluid from the patient taken by lumber puncture.
Participants in the market should collaborate with clinicians, medical practitioners, and labs to invest in training of medical staff or hire trained staff in primary healthcare settings and remote areas.
Bacterial meningitis is becoming one of the major causes of morbidity and mortality. Participants in the EMEA meningitis diagnostic testing market are taking advantage of this opportunity to enable rapid identification of the aetiological agent of meningitis. Such innovations are benefitting healthcare providers participating in clinical and public health management.
Since microbiological culture is complex, slow, and often impacted by prior antimicrobial treatment of the patient, companies in the EMEA meningitis diagnostic testing market are increasing the availability of molecular diagnostic assays for bacterial detection. Distinguishing between meningitis caused by meningococcus, pneumococcus, and others is becoming an important aspect of detection techniques.
Rapid diagnostic tests are significantly changing the EMEA meningitis diagnostic testing market. Companies are offering new lateral flow tests for the diagnosis of Neisseria meningitides, MeningoSpeed, and other bacteria to support rapid outbreak detection in Africa. The microbial diagnosis of meningitis is currently based on culture or more frequently on polymerase chain reaction (PCR) tests carried out by national reference laboratories (NRLs) on a sample of cerebrospinal fluid (CSF).
PCR tests require the maintaining of sample in a cold chain in primary health care centers (PHCs) and during transportation to the NRL. However, this makes the early identification of circulating strains difficult. In order to reduce the time needed to detect circulating strains, healthcare companies are developing diagnostic tests that can be used at bedside.
|
Attribute |
Detail |
|
Market Size Value in 2020 |
US$ 55.95 Mn |
|
Market Forecast Value in 2031 |
US$ 83.51 Mn |
|
Growth Rate (CAGR) |
3.7% |
|
Forecast Period |
2021–2031 |
|
Historical Data Available for |
2017–2019 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes cross segment analysis as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
EMEA meningitis diagnostic testing market is expected to reach the value of US$ 83.51 Mn by 2031
EMEA meningitis diagnostic testing market to expand at a CAGR of 3.7% from 2021 to 2031
Meningitis diagnostic testing market in EMEA is driven by rise in healthcare expenditure led by surge in awareness about different healthcare programs and availability of cost-effective diagnostic methods.
The lateral flow assay segment is projected to account for major share of the meningitis diagnostic testing market in EMEA during the forecast period.
Key players operating in the EMEA meningitis diagnostic testing market include Thermo Fisher Scientific, Inc., Abbott Laboratories, BioFire Diagnostics, Bio-Rad Laboratories, Inc., ELITechGroup
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Europe and Middle East & Africa Meningitis Diagnostic Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Success Factors for Top Players
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid /long term impact)
5.3. Key Industry Developments (product launch, product approvals, business expansion, etc.)
5.4. Regulatory Scenario
6. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, By Product, 2017–2031
6.3.1. Latex Agglutination Tests
6.3.2. Lateral Flow Assay
6.3.3. PCR Assay
6.3.4. ELISA Tests
6.3.5. Culture Test
6.3.6. Others
6.4. Market Attractiveness Analysis, By Product
7. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Type, 2017–2031
7.3.1. Syndromic Full Multiplex Panel
7.3.2. Low Plex Panel
7.4. Market Attractiveness Analysis, By Type
8. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, By End-user, 2017–2031
8.4. Market Attractiveness Analysis, By End-user
9. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Region
9.1. Key Findings
9.2. Market Value Forecast, By Region
10. Europe Meningitis Diagnostic Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, By Product, 2017–2031
10.2.1. Latex Agglutination Tests
10.2.2. Lateral Flow Assay
10.2.3. PCR Assay
10.2.4. ELISA Tests
10.2.5. Culture Test
10.2.6. Others
10.3. Market Value Forecast, By Type, 2017–2031
10.3.1. Syndromic Full Multiplex Panel
10.3.2. Low Plex Panel
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Diagnostic Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. Germany
10.5.1.1. Market Value Forecast, by Product, 2017–2031
10.5.1.1.1. Latex Agglutination Tests
10.5.1.1.2. Lateral Flow Assay
10.5.1.1.3. PCR Assay
10.5.1.1.4. ELISA Tests
10.5.1.1.5. Culture Test
10.5.1.1.6. Others
10.5.1.2. Market Value Forecast, by Type, 2017–2031
10.5.1.2.1. Syndromic Full Multiplex Panel
10.5.1.2.2. Low Plex Panel
10.5.1.3. Market Value Forecast, by End-user, 2017–2031
10.5.1.3.1. Hospitals
10.5.1.3.2. Diagnostic Centers
10.5.1.3.3. Others
10.5.2. U.K.
10.5.2.1. Market Value Forecast, by Product, 2017–2031
10.5.2.1.1. Latex Agglutination Tests
10.5.2.1.2. Lateral Flow Assay
10.5.2.1.3. PCR Assay
10.5.2.1.4. ELISA Tests
10.5.2.1.5. Culture Test
10.5.2.1.6. Others
10.5.2.2. Market Value Forecast, by Type, 2017–2031
10.5.2.2.1. Syndromic Full Multiplex Panel
10.5.2.2.2. Low Plex Panel
10.5.2.3. Market Value Forecast, by End-user, 2017–2031
10.5.2.3.1. Hospitals
10.5.2.3.2. Diagnostic Centers
10.5.2.3.3. Others
10.5.3. France
10.5.3.1. Market Value Forecast, by Product, 2017–2031
10.5.3.1.1. Latex Agglutination Tests
10.5.3.1.2. Lateral Flow Assay
10.5.3.1.3. PCR Assay
10.5.3.1.4. ELISA Tests
10.5.3.1.5. Culture Test
10.5.3.1.6. Others
10.5.3.2. Market Value Forecast, by Type, 2017–2031
10.5.3.2.1. Syndromic Full Multiplex Panel
10.5.3.2.2. Low Plex Panel
10.5.3.3. Market Value Forecast, by End-user, 2017–2031
10.5.3.3.1. Hospitals
10.5.3.3.2. Diagnostic Centers
10.5.3.3.3. Others
10.5.4. Italy
10.5.4.1. Market Value Forecast, by Product, 2017–2031
10.5.4.1.1. Latex Agglutination Tests
10.5.4.1.2. Lateral Flow Assay
10.5.4.1.3. PCR Assay
10.5.4.1.4. ELISA Tests
10.5.4.1.5. Culture Test
10.5.4.1.6. Others
10.5.4.2. Market Value Forecast, by Type, 2017–2031
10.5.4.2.1. Syndromic Full Multiplex Panel
10.5.4.2.2. Low Plex Panel
10.5.4.3. Market Value Forecast, by End-user, 2017–2031
10.5.4.3.1. Hospitals
10.5.4.3.2. Diagnostic Centers
10.5.4.3.3. Others
10.5.5. Spain
10.5.5.1. Market Value Forecast, by Product, 2017–2031
10.5.5.1.1. Latex Agglutination Tests
10.5.5.1.2. Lateral Flow Assay
10.5.5.1.3. PCR Assay
10.5.5.1.4. ELISA Tests
10.5.5.1.5. Culture Test
10.5.5.1.6. Others
10.5.5.2. Market Value Forecast, by Type, 2017–2031
10.5.5.2.1. Syndromic Full Multiplex Panel
10.5.5.2.2. Low Plex Panel
10.5.5.3. Market Value Forecast, by End-user, 2017–2031
10.5.5.3.1. Hospitals
10.5.5.3.2. Diagnostic Centers
10.5.5.3.3. Others
10.5.6. Benelux
10.5.6.1. Market Value Forecast, by Product, 2017–2031
10.5.6.1.1. Latex Agglutination Tests
10.5.6.1.2. Lateral Flow Assay
10.5.6.1.3. PCR Assay
10.5.6.1.4. ELISA Tests
10.5.6.1.5. Culture Test
10.5.6.1.6. Others
10.5.6.2. Market Value Forecast, by Type, 2017–2031
10.5.6.2.1. Syndromic Full Multiplex Panel
10.5.6.2.2. Low Plex Panel
10.5.6.3. Market Value Forecast, by End-user, 2017–2031
10.5.6.3.1. Hospitals
10.5.6.3.2. Diagnostic Centers
10.5.6.3.3. Others
10.5.7. Poland
10.5.7.1. Market Value Forecast, by Product, 2017–2031
10.5.7.1.1. Latex Agglutination Tests
10.5.7.1.2. Lateral Flow Assay
10.5.7.1.3. PCR Assay
10.5.7.1.4. ELISA Tests
10.5.7.1.5. Culture Test
10.5.7.1.6. Others
10.5.7.2. Market Value Forecast, by Type, 2017–2031
10.5.7.2.1. Syndromic Full Multiplex Panel
10.5.7.2.2. Low Plex Panel
10.5.7.3. Market Value Forecast, by End-user, 2017–2031
10.5.7.3.1. Hospitals
10.5.7.3.2. Diagnostic Centers
10.5.7.3.3. Others
10.5.8. Norway
10.5.8.1. Market Value Forecast, by Product, 2017–2031
10.5.8.1.1. Latex Agglutination Tests
10.5.8.1.2. Lateral Flow Assay
10.5.8.1.3. PCR Assay
10.5.8.1.4. ELISA Tests
10.5.8.1.5. Culture Test
10.5.8.1.6. Others
10.5.8.2. Market Value Forecast, by Type, 2017–2031
10.5.8.2.1. Syndromic Full Multiplex Panel
10.5.8.2.2. Low Plex Panel
10.5.8.3. Market Value Forecast, by End-user, 2017–2031
10.5.8.3.1. Hospitals
10.5.8.3.2. Diagnostic Centers
10.5.8.3.3. Others
10.5.9. Sweden
10.5.9.1. Market Value Forecast, by Product, 2017–2031
10.5.9.1.1. Latex Agglutination Tests
10.5.9.1.2. Lateral Flow Assay
10.5.9.1.3. PCR Assay
10.5.9.1.4. ELISA Tests
10.5.9.1.5. Culture Test
10.5.9.1.6. Others
10.5.9.2. Market Value Forecast, by Type, 2017–2031
10.5.9.2.1. Syndromic Full Multiplex Panel
10.5.9.2.2. Low Plex Panel
10.5.9.3. Market Value Forecast, by End-user, 2017-2031
10.5.9.3.1. Hospitals
10.5.9.3.2. Diagnostic Centers
10.5.9.3.3. Others
10.5.10. Denmark
10.5.10.1. Market Value Forecast, by Product, 2017–2031
10.5.10.1.1. Latex Agglutination Tests
10.5.10.1.2. Lateral Flow Assay
10.5.10.1.3. PCR Assay
10.5.10.1.4. ELISA Tests
10.5.10.1.5. Culture Test
10.5.10.1.6. Others
10.5.10.2. Market Value Forecast, by Type, 2017–2031
10.5.10.2.1. Syndromic Full Multiplex Panel
10.5.10.2.2. Low Plex Panel
10.5.10.3. Market Value Forecast, by End-user, 2017–2031
10.5.10.3.1. Hospitals
10.5.10.3.2. Diagnostic Centers
10.5.10.3.3. Others
10.5.11. Finland
10.5.11.1. Market Value Forecast, by Product, 2017–2031
10.5.11.1.1. Latex Agglutination Tests
10.5.11.1.2. Lateral Flow Assay
10.5.11.1.3. PCR Assay
10.5.11.1.4. ELISA Tests
10.5.11.1.5. Culture Test
10.5.11.1.6. Others
10.5.11.2. Market Value Forecast, by Type, 2017–2031
10.5.11.2.1. Syndromic Full Multiplex Panel
10.5.11.2.2. Low Plex Panel
10.5.11.3. Market Value Forecast, by End-user, 2017–2031
10.5.11.3.1. Hospitals
10.5.11.3.2. Diagnostic Centers
10.5.11.3.3. Others
10.5.12. Austria
10.5.12.1. Market Value Forecast, by Product, 2017–2031
10.5.12.1.1. Latex Agglutination Tests
10.5.12.1.2. Lateral Flow Assay
10.5.12.1.3. PCR Assay
10.5.12.1.4. ELISA Tests
10.5.12.1.5. Culture Test
10.5.12.1.6. Others
10.5.12.2. Market Value Forecast, by Type, 2017–2031
10.5.12.2.1. Syndromic Full Multiplex Panel
10.5.12.2.2. Low Plex Panel
10.5.12.3. Market Value Forecast, by End-user, 2017–2031
10.5.12.3.1. Hospitals
10.5.12.3.2. Diagnostic Centers
10.5.12.3.3. Others
10.5.13. Switzerland
10.5.13.1. Market Value Forecast, by Product, 2017–2031
10.5.13.1.1. Latex Agglutination Tests
10.5.13.1.2. Lateral Flow Assay
10.5.13.1.3. PCR Assay
10.5.13.1.4. ELISA Tests
10.5.13.1.5. Culture Test
10.5.13.1.6. Others
10.5.13.2. Market Value Forecast, by Type, 2017–2031
10.5.13.2.1. Syndromic Full Multiplex Panel
10.5.13.2.2. Low Plex Panel
10.5.13.3. Market Value Forecast, by End-user, 2017–2031
10.5.13.3.1. Hospitals
10.5.13.3.2. Diagnostic Centers
10.5.13.3.3. Others
10.5.14. Rest of Europe
10.5.14.1. Market Value Forecast, by Product, 2017–2031
10.5.14.1.1. Latex Agglutination Tests
10.5.14.1.2. Lateral Flow Assay
10.5.14.1.3. PCR Assay
10.5.14.1.4. ELISA Tests
10.5.14.1.5. Culture Test
10.5.14.1.6. Others
10.5.14.2. Market Value Forecast, by Type, 2017–2031
10.5.14.2.1. Syndromic Full Multiplex Panel
10.5.14.2.2. Low Plex Panel
10.5.14.3. Market Value Forecast, by End-user, 2017–2031
10.5.14.3.1. Hospitals
10.5.14.3.2. Diagnostic Centers
10.5.14.3.3. Others
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Type
10.6.3. By End-user
10.6.4. By Country
11. Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Latex Agglutination Tests
11.2.2. Lateral Flow Assay
11.2.3. PCR Assay
11.2.4. ELISA Tests
11.2.5. Culture Test
11.2.6. Others
11.3. Market Value Forecast, by Type, 2017–2031
11.3.1. Syndromic Full Multiplex Panel
11.3.2. Low Plex Panel
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Diagnostic Centers
11.4.3. Others
11.5. Market Value Forecast, by Country, 2017–2031
11.5.1. GCC Countries
11.5.1.1. Market Value Forecast, by Product, 2017–2031
11.5.1.1.1. Latex Agglutination Tests
11.5.1.1.2. Lateral Flow Assay
11.5.1.1.3. PCR Assay
11.5.1.1.4. ELISA Tests
11.5.1.1.5. Culture Test
11.5.1.1.6. Others
11.5.1.2. Market Value Forecast, by Type, 2017–2031
11.5.1.2.1. Syndromic Full Multiplex Panel
11.5.1.2.2. Low Plex Panel
11.5.1.3. Market Value Forecast, by End-user, 2017–2031
11.5.1.3.1. Hospitals
11.5.1.3.2. Diagnostic Centers
11.5.1.3.3. Others
11.5.2. South Africa
11.5.2.1. Market Value Forecast, by Product, 2017–2031
11.5.2.1.1. Latex Agglutination Tests
11.5.2.1.2. Lateral Flow Assay
11.5.2.1.3. PCR Assay
11.5.2.1.4. ELISA Tests
11.5.2.1.5. Culture Test
11.5.2.1.6. Others
11.5.2.2. Market Value Forecast, by Type, 2017–2031
11.5.2.2.1. Syndromic Full Multiplex Panel
11.5.2.2.2. Low Plex Panel
11.5.2.3. Market Value Forecast, by End-user, 2017–2031
11.5.2.3.1. Hospitals
11.5.2.3.2. Diagnostic Centers
11.5.2.3.3. Others
11.5.3. Rest of Middle East & Africa
11.5.3.1. Market Value Forecast, by Product, 2017–2031
11.5.3.1.1. Latex Agglutination Tests
11.5.3.1.2. Lateral Flow Assay
11.5.3.1.3. PCR Assay
11.5.3.1.4. ELISA Tests
11.5.3.1.5. Culture Test
11.5.3.1.6. Others
11.5.3.2. Market Value Forecast, by Type, 2017–2031
11.5.3.2.1. Syndromic Full Multiplex Panel
11.5.3.2.2. Low Plex Panel
11.5.3.3. Market Value Forecast, by End-user, 2017–2031
11.5.3.3.1. Hospitals
11.5.3.3.2. Diagnostic Centers
11.5.3.3.3. Others
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Type
11.6.3. By End-user
11.6.4. By Country
12. Competition Landscape
12.1. Company Profiles
12.1.1. Thermo Fisher Scientific, Inc.
12.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.1.2. Product Portfolio
12.1.1.3. SWOT Analysis
12.1.1.4. Strategic Overview
12.1.2. BioFire Diagnostics
12.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.2.2. Product Portfolio
12.1.2.3. SWOT Analysis
12.1.2.4. Strategic Overview
12.1.3. Fast Track Diagnostics Ltd. (FTD) – Siemens Healthineers
12.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.3.2. Product Portfolio
12.1.3.3. SWOT Analysis
12.1.3.4. Strategic Overview
12.1.4. Bio-Rad Laboratories, Inc.
12.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.4.2. Product Portfolio
12.1.4.3. SWOT Analysis
12.1.4.4. Strategic Overview
12.1.5. IMMY
12.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.5.2. Product Portfolio
12.1.5.3. SWOT Analysis
12.1.5.4. Strategic Overview
12.1.6. Nanosphere (Luminex Corporation)
12.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.6.2. Product Portfolio
12.1.6.3. SWOT Analysis
12.1.6.4. Strategic Overview
12.1.7. Seegene, Inc.
12.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.7.2. Product Portfolio
12.1.7.3. SWOT Analysis
12.1.7.4. Strategic Overview
12.1.8. Qnostics
12.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.8.2. Product Portfolio
12.1.8.3. SWOT Analysis
12.1.8.4. Strategic Overview
12.1.9. ELITechGroup
12.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.9.2. Product Portfolio
12.1.9.3. SWOT Analysis
12.1.9.4. Strategic Overview
12.1.10. Abbott Laboratories
12.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.10.2. Product Portfolio
12.1.10.3. SWOT Analysis
12.1.10.4. Strategic Overview
12.1.11. Other Prominent Players
List of Table
Table 01: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by Product Type, 2017–2031
Table 02: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 03: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 06: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 07: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-User, 2017–2031
Table 08: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 10: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 11: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 13: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 14: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 15: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 16: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 17: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 18: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 19: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 20: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 22: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 23: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 24: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 25: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 26: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 27: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 28: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 29: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 30: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 31: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 32: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 33: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 34: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 35: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 36: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 37: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 38: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 39: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 40: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 41: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 42: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 43: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 44: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 45: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 46: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 47: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 48: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 49: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 50: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 51: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 52: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 53: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 54: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 55: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 56: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 57: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 58: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 59: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 60: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 61: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 62: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
Table 63: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figure
Figure 01: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Product Type (2020)
Figure 03: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by End-user (2020)
Figure 04: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Panel Type (2020)
Figure 05: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Region (2020)
Figure 06: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 07: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Latex Agglutination Tests, 2017–2031
Figure 08: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Lateral Flow Assay, 2017–2031
Figure 09: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by PCR Assay, 2017–2031
Figure 10: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by ELISA Tests, 2017–2031
Figure 11: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Culture Test, 2017–2031
Figure 12: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by others, 2017–2031
Figure 13: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 14: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 15: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Syndromic Full Multiplex Panel, 2017–2031
Figure 16: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Low Plex Panel, 2017–2031
Figure 17: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 18: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 19: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Hospitals, 2017–2031
Figure 20: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Diagnostic Centers, 2017–2031
Figure 21: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Others, 2017–2031
Figure 22: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 23: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Region, 2020 and 2031
Figure 24: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Region, 2021-2031
Figure 25: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 26: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 27: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 28: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 29: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by End-User, 2020 and 2031
Figure 30: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-User, 2021–2031
Figure 31: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Country, 2020 and 2031
Figure 32: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Country, 2021–2031
Figure 33: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 34: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 35: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 36: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 37: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 38: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 39: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 40: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 41: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 42: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 43: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 44: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 45: France Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 46: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 47: France Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 48: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 49: France Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 50: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 51: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 52: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 53: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 54: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 55: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 56: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 57: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 58: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 59: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 60: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 61: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 62: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 63: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 64: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 65: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 66: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 67: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 68: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 69: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 70: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 71: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 72: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 73: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 74: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 75: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 76: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 77: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 78: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 79: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 80: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 81: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 82: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 83: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 84: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 85: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 86: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 87: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 88: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 89: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 90: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 91: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 92: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 93: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 94: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 95: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 96: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 97: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 98: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 99: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 100: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 101: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 102: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 103: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 104: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 105: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 106: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 107: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 108: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 109: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 110: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 111: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 112: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 113: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 114: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 115: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 116: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 117: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 118: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 119: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 120: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 121: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 122: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 123: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 124: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 125: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 126: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 127: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 128: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 129: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 130: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 131: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 132: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 133: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 134: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 135: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 136: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 137: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 138: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 139: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
Figure 140: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021–2031
Figure 141: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 142: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
EMEA Meningitis Diagnostic Testing Market
